Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a combination of three antibiotics—amoxicillin, sulfamethoxazole, and trimethoprim. Amoxicillin is a penicillin-type beta-lactam antibiotic that inhibits bacterial cell wall synthesis. Sulfamethoxazole is a sulfonamide antibiotic that inhibits dihydropteroate synthase, interfering with folic acid synthesis in bacteria. Trimethoprim inhibits bacterial dihydrofolate reductase, blocking another step in folic acid production. The combination of sulfamethoxazole and trimethoprim (often known as co-trimoxazole) acts synergistically to inhibit sequential steps in the bacterial folic acid pathway, resulting in bactericidal activity[3][6][8]. Amoxicillin works via a different mechanism targeting cell wall synthesis[1][3]. This triple combination would theoretically provide broad-spectrum antibacterial coverage by combining two mechanisms—cell wall inhibition and dual blockade of folate metabolism.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on amoxicillin + sulfamethoxazole + trimethoprim.